UNC?1021

CAS No. 1322591-19-4

UNC?1021( —— )

Catalog No. M35814 CAS No. 1322591-19-4

UNC 1021 is a selective L3MBTL3 inhibitor (IC50 = 0.048 μM).

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 36 In Stock
10MG 55 In Stock
25MG 107 In Stock
50MG 166 In Stock
100MG 267 In Stock
200MG 369 In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    UNC?1021
  • Note
    Research use only, not for human use.
  • Brief Description
    UNC 1021 is a selective L3MBTL3 inhibitor (IC50 = 0.048 μM).
  • Description
    UNC1021 is a selective L3MBTL3 inhibitor with an IC50 of 0.048 μM.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Chromatin/Epigenetic
  • Target
    Epigenetic Reader Domain
  • Recptor
    Epigenetic Reader Domain
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    1322591-19-4
  • Formula Weight
    438.61
  • Molecular Formula
    C26H38N4O2
  • Purity
    >98% (HPLC)
  • Solubility
    In Vitro:?DMSO : ≥ 9.09 mg/mL (20.72 mM )
  • SMILES
    O=C(N1CCC(CC1)N1CCCC1)c1ccc(cc1)C(=O)N1CCC(CC1)N1CCCC1
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. James LI, et al. Small-molecule ligands of methyl-lysine binding proteins: optimization of selectivity for L3MBTL3. J Med Chem. 2013 Sep 26;56(18):7358-71.?
molnova catalog
related products
  • JQAD1

    JQAD1 is a potent and selective histone acetyltransferase EP300 degrader (PROTAC?; DC50≤ 31.6 nM); comprises an EP300 inhibitor, A485, joined by a linker to a cereblon E3 ligase ligand.

  • CCT077791

    CCT077791 is a potent inhibitor of p300 and PCAF histone acetyltransferase activity for cancer research.

  • SGC-SMARCA-BRDVIII

    SGC-SMARCA-BRDVIII is a potent and selective inhibitor of SMARCA2, SMARCA4, PB1(2), PB1(3) and PB1(5) with Kds of 35 nM, 36 nM, 3.7 μM, 2.0 μM and 13 nM, respectively.